The FDA has extended its review of zenocutuzumab's in NRG1+ NSCLC and PDAC to February 2025, with efficacy and safety data ...
In an interview, Colton Ladbury, MD, discussed new insights from a study and expanded on total marrow irradiation’s potential ...
Amer Zeidan, MBBS, discusses how ring sideroblasts status affects using luspatercept in patients with myelodysplastic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback